

# Chinese herbal tea to enhance stopping smoking

<b>Submission date</b> 18/12/2021	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 21/12/2021	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 31/01/2025	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

It is known that stopping smoking can help prevent many diseases and save lives. It's difficult to stop smoking and resist nicotine dependence. Traditional Chinese herbal can help relieve cough and tea, as the routine behaviour can remind of stopping smoking. Thus, this study aims to find whether Chinese herbal tea can help smoking cessation and strengthen the faith in stopping smoking.

### Who can participate?

Patients are willing to seek treatment to stop smoking in a smoking cessation clinic in China.

### What does the study involve?

Participants will be randomly allocated to one of two groups as conventional treatment or combination with Chinese herbal tea for 4 weeks. After 4 weeks, participants will have the right to choose whether receive Chinese herbal tea for 8 weeks.

Participants will be asked to give blood samples at the beginning of the study and at the 4th week to ensure basic safety. Participants will get about 12-week treatment for smoking cessation and will complete the online questionnaires and assessments on the first day and every week to ensure the effectiveness of abstinence.

### What are the possible benefits and risks of participating?

Participants will get 12-week treatment for smoking cessation and free Chinese herbal tea. Participants may suffer from nicotine withdrawal symptoms such as sick, dizziness.

### Where is the study run from?

Beijing University of Chinese medicine and smoking cessation clinic of Beijing Chaoyang Hospital (China)

### When is the study starting and how long is it expected to run for?

June 2021 to June 2022

### Who is funding the study?

Beijing University of Chinese medicine (China)

Who is the main contact?

1. PhD. Chun-li Lu  
Jennylyu@bucme.edu.cn
2. Prof. Jian-ping Liu  
Liujp@bucm.edu.cn

## Contact information

### Type(s)

Public

### Contact name

Dr Chun-li Lu

### ORCID ID

<https://orcid.org/0000-0003-2939-1327>

### Contact details

11 Bei San Huan Dong Lu Chaoyang District  
Beijing  
China  
100029  
+86 15652387872  
Jennylyu@bucm.edu.cn

### Type(s)

Principal investigator

### Contact name

Prof Jian-ping Liu

### ORCID ID

<https://orcid.org/0000-0002-0320-061X>

### Contact details

11 Bei San Huan Dong Lu Chaoyang District  
Beijing  
China  
100029  
+86 1064286760  
Liujp@bucm.edu.cn

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

### ClinicalTrials.gov (NCT)

Nil known

**Protocol serial number**

Nil known

## Study information

**Scientific Title**

Effectiveness of Chinese herbal tea combined with conventional therapy for patients to stopping smoking in smoking cessation clinic: a randomized controlled trial

**Acronym**

CHESS

**Study objectives**

Chinese herbal tea can relieve the cough and heat syndrome (based on traditional Chinese medicine theory), thus Chinese herbal tea combined with conventional therapy may have superior effect for smoking cessation and increase the compliance of smokers to stop smoking.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Approved 12/06/2021, Ethics Committee of Beijing Chaoyang Hospital, Capital Medical University (8 Nan lu Workers Stadium, Chaoyang district, Beijing, China; +86 010-85231484; cyyunli2019@163.com), ref:2021--622

**Study design**

Single-centre interventional randomized controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Treatment for patients who are willing to stop smoking in smoking cessation clinic

**Interventions**

Experimental group: Chinese herbal tea combined with conventional therapy (based on physician prescription) for 4 weeks.

Control group: conventional therapy (based on physician prescription) for 4 weeks.

After 4-week treatment, all participants can choose by their own will to receive which treatment for 8 weeks, we conduct the follow-up for these 8 weeks.

Participants are randomly allocated to groups using the sealed envelope method.

**Intervention Type**

Mixed

**Primary outcome(s)**

1. Carbon monoxide expiratory volume is measured using Carbon monoxide detector at baseline, 1 day, 4 weeks.
2. Abstinence rate is measured using patients' self-report at baseline, 1 day, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks.
3. Nicotine dependence is measured using Fagerstrom test for nicotine dependence (FTND) at baseline, 1 day, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks.
4. Implementation outcomes of combined Chinese herbal tea during smoking cessation treatment is measured using questionnaire and interview (containing acceptability, appropriateness, feasibility, adoption, fidelity, and sustainability) at baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks.

### **Key secondary outcome(s)**

1. Nicotine withdrawal symptoms are measured using Minnesota Nicotine Withdrawal Scale (MNWS) at baseline, 1 day, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks.
2. Traditional Chinese medicine (TCM) syndrome is measured using TCM scale at baseline, 1 week, 4 weeks, 8 weeks, 12 weeks.
3. Safety outcomes are measured using blood examination (ALT, AST, GGT, BUN, Cr, UA, biochemical electrolyte) at baseline and 4 weeks.
4. Adverse events are measured using patients' self-report at 1 day, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks during the whole course of study.

### **Completion date**

30/06/2022

## **Eligibility**

### **Key inclusion criteria**

1. Patients in smoking cessation clinic seeking treatment.
2. Patients eligible for conventional medication.
3. The patients voluntarily sign the informed consent.

### **Participant type(s)**

Other

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Sex**

All

### **Key exclusion criteria**

1. Patients with serious diseases of the heart, lung, kidney and hematopoietic system.
2. Pregnant or lactating women.
3. Patients who are participating in other clinical trials.
4. Patients allergic to licorice and platycodon grandiflorum.
5. Patients with allergies to smoking cessation medications or similar ingredients.

6. Patients who are receiving other TCM treatments and whose TCM prescriptions include Gansui, Jingdaji, Haizao, and Yuanhua.

**Date of first enrolment**

01/02/2022

**Date of final enrolment**

30/03/2022

## **Locations**

**Countries of recruitment**

China

**Study participating centre**

**Beijing Chaoyang Hospital, Capital Medical University**

8 Nan lu Workers Stadium

Chaoyang district

Beijing

China

100020

## **Sponsor information**

**Organisation**

Beijing University of Chinese Medicine

**ROR**

<https://ror.org/05damtm70>

## **Funder(s)**

**Funder type**

University/education

**Funder Name**

Beijing University of Chinese medicine

## **Results and Publications**

## Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request (Jennylyu@bucme.edu.cn)

## IPD sharing plan summary

Available on request

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Abstract results</a>	P15.06LB	25/04/2024	31/01/2025	No	No